Quest Diagnostics sales and marketing update

Quest launched two blood tests in the U.S. to aid in diagnosing early stage rheumatoid arthritis. The tests are based on the 14-3-3n marker, to which Quest has exclusive, U.S. rights from Augurex Life Sciences Corp. (Vancouver, B.C.) under an October 2012 deal. The marker is a protein that is elevated in the blood of RA patients that is relatively absent in healthy people and those with other types of autoimmune conditions (see BioCentury, Oct. 15, 2012). ...